...
首页> 外文期刊>日本臨牀 >Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans
【24h】

Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans

机译:概述动脉硬化闭塞症的诊断,治疗和治疗血管生成

获取原文
获取原文并翻译 | 示例
           

摘要

Arteriosclerosis of the extremities is a disease of the blood vessels characterized by hardening and/or narrowing of the arteries that supply the legs and feet. This causes a decrease in blood flow that can injure nerves and other tissues. Therapeutic angiogenesis using angiogenic growth factor is expected to be a new treatment for patients with critical limb ischemia. The first human clinical trial treating peripheral vascular disease was started in 1994 using vascular endothelial growth factor. To date, other potent angiogenic growth factors, such as hepatocyte growth factor(HGF), have been also estimated in clinical trials for peripheral arterial disease. Several results from phase 1 or 2 trials using HGF gene were encouraging. Phase 3 trials are now ongoing and their results are expected.
机译:肢体的动脉硬化是一种血管的疾病,其特征在于提供供应腿部和脚的动脉的硬化和/或缩小。 这导致血流减少,可以损伤神经和其他组织。 预计使用血管生成生长因子的治疗血管生成是临界肢体缺血患者的新治疗方法。 使用血管内皮生长因子,在1994年开始治疗周围血管疾病的第一个人类临床试验。 迄今为止,还估计了外周动脉疾病的临床试验中的其他有效的血管生成生长因子,例如肝细胞生长因子(HGF)。 使用HGF基因的阶段1或2试验的几种结果令人鼓舞。 第3阶段试验现在正在进行,预期结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号